Sirexatamab is a monoclonal antibody commercialized by Leap Therapeutics, with a leading Phase II program in Gastric Cancer. According to Globaldata, it is involved in 14 clinical trials, of which 6 were completed, 5 are ongoing, and 3 were terminated. GlobalData uses proprietary data and analytics to provide a complete picture of Sirexatamab’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

Smarter leaders trust GlobalData

The revenue for Sirexatamab is expected to reach an annual total of $59 mn by 2039 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

Sirexatamab Overview

Sirexatamab (DKN-01, LY-2812176) is under development for the treatment of bile duct cancer,  colorectal cancer, advanced gynecological cancers and extrahepatic bile duct cancer. The drug candidate is administered intravenously. It is a monoclonal antibody targeting dickkopf homolog 1 (Dkk-1). The drug candidate was also under development for the treatment of relapsed or refractory multiple myeloma, metastatic castration-resistant prostate cancer, non-small cell lung cancer, esophageal cancer, fallopian tube cancer, adenocarcinoma of the gastroesophageal junction, epithelial ovarian cancer, peritoneal cancer, endometrial cancer, carcinosarcoma (uterine cancer), gallbladder cancer.

Leap Therapeutics Overview

Leap Therapeutics is a clinical-stage biopharmaceutical company. It develops novel and targeted drugs to treat patients with different types of cancer. The company’s pipeline includes DKN-01, FL-301, FL-302 and FL-501. DKN-1 is a monoclonal antibody that targets the Dickkopf-1 (DKK-1) protein, intended for the treatment of gastroesophageal cancer, colorectal cancer and gynecological cancer. FL-301 is a monoclonal antibody that targets Claudin18.2 and is being tested in patients with gastric and pancreatic cancer. FL-302 is a tetravalent bispecific antibody that targets both Claudin18.2 and CD137. FL-501 is an antibody designed to neutralize GDF15 and prevent the binding to its receptor. Leap Therapeutics is headquartered in Cambridge, Massachusetts, the US.
The operating loss of the company was US$87 million in FY2023, compared to an operating loss of US$56.8 million in FY2022. The net loss of the company was US$81.4 million in FY2023, compared to a net loss of US$54.6 million in FY2022.

For a complete picture of Sirexatamab’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.

This content was updated on 11 March 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.